Press release - 04/07/2024 Antibody can improve immune cell therapy against leukemia Scientists from the German Cancer Research Center (DKFZ) and Heidelberg University Hospital (UKHD) have shown that the combination of therapeutic immune cells, known as CAR T cells, and a bispecific antibody could improve the treatment of leukaemia. In the culture dish and in mice, they tested CAR-T cells directed against the B-cell marker CD19 in combination with bispecific antibodies that bind to the B-cell-specific protein CD20. https://www.gesundheitsindustrie-bw.de/en/article/press-release/antibody-can-improve-immune-cell-therapy-against-leukemia
Press release - 03/01/2025 New approaches against metastatic breast cancer: mini-tumors from circulating cancer cells Tumor cells circulating in the blood are the "germ cells" of breast cancer metastases. They are rare and could not be propagated in the culture dish until now, which made research into therapy resistance difficult. A team from the DKFZ, the Heidelberg Stem Cell Institute HI-STEM and the NCT Heidelberg has now succeeded for the first time in cultivating stable tumor organoids directly from blood samples of breast cancer patients.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approaches-against-metastatic-breast-cancer-mini-tumors-circulating-cancer-cells
Press release - 12/03/2025 Hepatic stellate cells control liver function and regeneration Until now, doctors knew hepatic stellate cells mainly as drivers of liver fibrosis. The actual functions have hardly been studied to date. Researchers from the German Cancer Research Center, the Mannheim Medical Faculty and Columbia University have now published that hepatic stellate cells control liver metabolism as well as liver regeneration and size. The results of the study could contribute to new therapeutic approaches for liver diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/hepatic-stellate-cells-control-liver-function-and-regeneration
Press release - 17/01/2024 AI-based support system for skin cancer diagnostics explains its decisions Artificial intelligence (AI) can help dermatologists to detect skin cancer. However, many dermatologists distrust the algorithms' decisions, which they cannot comprehend. Scientists at the German Cancer Research Center have now developed an AI-based support system for skin cancer diagnostics that explains its decisions.https://www.gesundheitsindustrie-bw.de/en/article/press-release/ai-based-support-system-skin-cancer-diagnostics-explains-its-decisions
Article - 14/09/2022 Theranostics of prostate cancer: the combination of radionuclide diagnostics and radionuclide therapy Using a low-level radiopharmaceutical that binds to the prostate-specific membrane antigen (PSMA), positron emission tomography/computed tomography can be used to visualise even small prostate cancer metastases. Developed by Heidelberg researchers, the radiopharmaceutical is a modified radionuclide diagnostic agent that has been coupled with a powerful emitter and used as a therapeutic tracer to irradiate and destroy cancer cells from within.https://www.gesundheitsindustrie-bw.de/en/article/news/theranostics-prostate-cancer-combination-radionuclide-diagnostics-and-radionuclide-therapy
Press release - 06/07/2021 High-throughput metabolic profiling of single cells Scientists from the EMBL and the German Cancer Research Center have presented a new method for generating metabolic profiles of individual cells. The method, which combines fluorescence microscopy and a specific form of mass spectroscopy, can analyze over a hundred metabolites and lipids from more than a thousand individual cells per hour. Researchers expect the method to better answer a variety of biomedical questions in the future.https://www.gesundheitsindustrie-bw.de/en/article/press-release/high-throughput-metabolic-profiling-single-cells
Press release - 19/09/2022 How stressed tumor cells escape cell death: new mechanism discovered Because of their highly active metabolism, many tumors are susceptible to a special type of cell death, ferroptosis. Nevertheless, cancer cells often manage to escape this fate. Scientists at the German Cancer Research Center have now discovered a new mechanism by which normal as well as cancer cells protect themselves against ferroptosis.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-stressed-tumor-cells-escape-cell-death-new-mechanism-discovered
TWYCE GmbH - 10/07/2024 Better immune response against prostate cancer thanks to new bispecific antibodies TWYCE, a Tübingen-based start-up spun off from the German Cancer Research Center in Heidelberg and the Faculty of Medicine at the University of Tübingen, is focused on developing a combinatorial therapy using two bispecific antibodies from bench to clinical practice. The founders aim to introduce an effective strategy for combating solid tumours, with initial proof of concept targeted at prostate cancer.https://www.gesundheitsindustrie-bw.de/en/article/news/better-immune-response-against-prostate-cancer-thanks-new-bispecific-antibodies
Press release - 02/09/2021 Blood vessels produce growth factor that promotes metastases On the one hand, blood vessels supply tumors with nutrients and, on the other, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a distant organ is promoted by factors whose production is induced by the primary tumor itself. Scientists have now identified a new growth factor produced by blood vessels that enables tumor cells to metastatically colonize organs.https://www.gesundheitsindustrie-bw.de/en/article/press-release/blood-vessels-produce-growth-factor-promotes-metastases
Press release - 25/04/2022 Reprogrammed macrophages promote spread of breast cancer Metastatic breast cancer cells abuse macrophages, a type of immune cell, to promote the settlement of cancer metastases in the lungs. The reprogrammed macrophages stimulate blood vessel cells to secrete a cocktail of metastasis-promoting proteins that are part of the so-called metastatic niche.https://www.gesundheitsindustrie-bw.de/en/article/press-release/reprogrammed-macrophages-promote-spread-breast-cancer
Press release - 22/02/2024 A new approach to recording cellular activities In living cells, a vast number of transient events occur simultaneously. The recording of these activities is a prerequisite for a molecular understanding of life. Scientists at the MPI for Medical Research in Heidelberg and their collaboration partners have created a novel technology that allows cellular events to be recorded through chemical labeling with fluorescent dyes for later analysis, opening up new ways to study cellular physiology.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-recording-cellular-activities
Press release - 13/06/2024 Which of the two DNA strands is damaged influences the cell's mutation profile Cancer genomes are the result of diverse mutation processes. Scientists have analyzed the molecular evolution of tumors after exposure to mutagenic chemicals. DNA lesions that persists unrepaired over several cell generations lead to sequence variations at the site of damage. This enabled the researchers to distinguish the contribution of the triggering lesion from that of the subsequent repair in shaping the mutation pattern.https://www.gesundheitsindustrie-bw.de/en/article/press-release/which-two-dna-strands-damaged-influences-cells-mutation-profile
Press release - 24/03/2021 Liver cancer: which patients benefit from immunotherapy? Immunotherapy using checkpoint inhibitors is effective in around a quarter of patients with liver cancer. However, to date, physicians have been unable to predict which patients would benefit from this type of treatment and which would not. Researchers from the German Cancer Research Center have now discovered that liver cancer caused by chronic inflammatory fatty liver disease does not respond to this treatment. On the contrary: in an…https://www.gesundheitsindustrie-bw.de/en/article/press-release/liver-cancer-which-patients-benefit-immunotherapy
Press release - 19/03/2021 New single-cell analysis of leucemic stem cells A new method allows stem cells and cancer stem cells to be studied at the single cell level and the resulting cell clones to be traced directly. Studying thousands of individual cells in parallel, the researchers combined the analysis of the genomic cancer mutations with the associated expression profiles.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-single-cell-analysis-leucemic-stem-cells
Press release - 26/07/2021 Vaccination against hereditary colorectal cancer successful in mice Scientists from the German Cancer Research Center and Heidelberg University Hospital have for the first time been able to delay the development of hereditary colorectal cancer with a protective vaccination. Mice with a hereditary predisposition to colorectal cancer survived significantly longer after vaccination than unvaccinated animals. Combining the vaccination with an anti-inflammatory drug increased the protective effect.https://www.gesundheitsindustrie-bw.de/en/article/press-release/vaccination-against-hereditary-colorectal-cancer-successful-mice
Value-based healthcare - 11/01/2023 High-quality healthcare pays off High-quality medical treatment is not only worthwhile for ill persons. The Division of Health Economics at the German Cancer Research Center in Heidelberg, headed up by Prof. Dr. Michael Schlander, together with researchers from Dresden, has carried out a cost-effectiveness analysis that shows that certified colon cancer centres provide not only better but also more cost-effective care than other clinics.https://www.gesundheitsindustrie-bw.de/en/article/news/high-quality-healthcare-pays
Press release - 25/10/2023 Epigenetically acting drugs could support cancer immunotherapy Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetically-acting-drugs-could-support-cancer-immunotherapy
Press release - 25/10/2023 Epigenetically acting drugs could support cancer immunotherapy Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetisch-wirkende-medikamente-koennten-krebs-immuntherapie-unterstuetzen
Article - 11/06/2019 New pathogens in beef and cow's milk contributing to the risk of cancer A team of researchers led by Nobel laureate Prof. Dr. med. Dr. h.c. mult. Harald zur Hausen has discovered a new type of infectious agent in dairy and meat products produced from European cattle that increases the risk for colon and breast cancer. These so-called Bovine Meat and Milk Factors (BMMFs) are small DNA molecules that are similar in sequence to both bacterial plasmids and certain viruses.https://www.gesundheitsindustrie-bw.de/en/article/news/new-pathogens-in-beef-and-cows-milk-contributing-to-the-risk-of-cancer
Press release - 09/12/2021 New research project in mathematical oncology A new interdisciplinary research project aims to uncover information that can help decode hereditary colon cancer with the aid of mathematical models. Mathematicians and tumour biologists of Heidelberg University, the Heidelberg Institute for Theoretical Studies, Heidelberg University Hospital, and the German Cancer Research Center are collaborating on the project.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-research-project-mathematical-oncology
Press release - 03/03/2022 Identifying Alzheimer's risks – as early as 17 years before diagnosis In order to develop approaches for the prevention and treatment of Alzheimer's dementia in clinical trials, it would be helpful to be able to identify people with a particularly high risk of developing the disease. But which biomarkers can indicate an increased likelihood of disease early on in symptom-free people who actually develop Alzheimer's later?https://www.gesundheitsindustrie-bw.de/en/article/press-release/identifying-alzheimers-risks-early-17-years-diagnosis
Press release - 29/11/2023 EU funds research into causes and new therapies for multiple sclerosis The progression of multiple sclerosis (MS) can usually be slowed down with medication, but a cure is currently not possible. It is now established that Epstein-Barr viruses are involved in the development of MS. However, it is not known how the pathogens trigger the disease. The European Union is now funding the international research consortium BEHIND-MS as part of its HORIZON Europe program.https://www.gesundheitsindustrie-bw.de/en/article/press-release/eu-foerdert-forschung-zu-ursachen-und-neuen-therapien-der-multiplen-sklerose
Press release - 16/05/2024 Colorectal cancer: tracking down subtypes Colorectal cancer differs from patient to patient. That is why scientists are looking for characteristic tumors markers that allow to make predictions about the likely response to certain therapies and the individual prognosis. The aim is to identify colorectal cancer subtypes so that these can then be treated in a customized manner. https://www.gesundheitsindustrie-bw.de/en/article/press-release/colorectal-cancer-tracking-down-subtypes
Press release - 24/05/2023 Epigenetic profiling identifies potential COPD treatment targets Impaired function of lung fibroblast is considered causative for symptoms of the incurable lung disease COPD (Chronic Obstructive Pulmonary Disease). Using high-resolution epigenetic profiling, German and British scientists have now identified potential targets for COPD treatment. The team detected early epigenetic changes in the genome of COPD fibroblasts, providing new insights into the disease pathogenesis and potential therapeutic avenues.https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetic-profiling-identifies-potential-copd-treatment-targets
Press release - 22/08/2024 Validated targets for personalized cancer immunotherapy Knowledge of the target structures for the immune cells is a basic prerequisite for the development of personalized cancer immunotherapies. Scientists from the German Cancer Research Center and the NCT Heidelberg are publishing a sensitive method based on mass spectroscopy to identify such tumor-specific "neoepitopes". The analytical method is designed to detect these low abundance protein fragments and requires minimal amounts of…https://www.gesundheitsindustrie-bw.de/en/article/press-release/validated-targets-personalized-cancer-immunotherapy